

Journal of Materials Chemistry B

Materials for biology and medicine

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: Q. Ding, Y. Wang, P. Zhang and L. Mei, *J. Mater. Chem. B*, 2024, DOI: 10.1039/D4TB02019G.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

ARTICLE

Breakthrough in Cancer Therapy: Lutetium Texaphyrin-Celecoxib Conjugate for Immune and Photodynamic Treatment

Qihang Ding^{a†}, Yue Wang^{b†}, Pengfei Zhang^{b*} and Ling Mei^{c*}Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

Immuno-photodynamic therapy (IPDT) has become a promising approach for cancer treatment. Innovative photosensitizers are essential to fully realize the potential of IPDT, specifically the complete elimination of tumors without recurrence. In this context, Jong Seung Kim *et al.* introduce a small molecule photosensitizer conjugate, LuCXB. This IPDT agent combines a celecoxib (cyclooxygenase-2 inhibitor) moiety with a near-infrared absorbing lutetium texaphyrin photocatalytic core. In aqueous solutions, the two components of LuCXB self-associate through inferred donor–acceptor interactions. As a result of this intramolecular association, LuCXB generates superoxide radicals ($O_2^{\cdot-}$) via a type I photodynamic pathway upon irradiation with 730 nm light. This serves as a primary defense against the tumor and enhances the IPDT effect. For in vivo applications, they developed a CD133-targeting, aptamer-functionalized exosome-based nanophotosensitizer (Ex-apt@LuCXB) aimed at targeting cancer stem cells. Ex-apt@LuCXB demonstrated excellent photosensitivity, satisfactory biocompatibility, and strong tumor-targeting capabilities. Under photoirradiation, Ex-apt@LuCXB amplifies IPDT and produces significant antitumor effects in liver and breast cancer mouse models. The therapeutic outcomes are attributed to a synergistic mechanism that combines antiangiogenesis with photoinduced cancer immunotherapy.

Cancer remains a significant global health issue, with current treatment methods often necessitating a delicate balance between efficacy and side effects [1]. Recently, immuno-photodynamic therapy (IPDT) has emerged as a promising novel treatment modality. In this study, Jong Seung Kim's team reported the potential application of an innovative Lutetium Texaphyrin-Celecoxib Conjugate (LuCXB) for IPDT [2]. This groundbreaking photosensitizer combines celecoxib, a cyclooxygenase-2 inhibitor, with a near-infrared absorbing lutetium texaphyrin photocatalytic core to enhance the effectiveness of photodynamic therapy and overcome challenges posed by hypoxic tumor microenvironments [3,4].

The conjugation of LuCXB results in the formation of a distinct photosensitizer by combining the cyclooxygenase-2 inhibitor (celecoxib) with a lutetium texaphyrin photocatalytic core. This unique combination not only facilitates the generation of superoxide radicals ($O_2^{\cdot-}$) through photocatalysis but also enables excitation using near-infrared light at 730 nm, allowing it to effectively operate within deep tissues. Traditional photodynamic therapy often relies on oxygen for producing reactive oxygen species (ROS), which limits its efficacy in hypoxic environments [5,6]. In contrast, LuCXB generates superoxide radicals through a Type I photodynamic pathway, ensuring its effectiveness even under hypoxic conditions.

Moreover, the study utilizes an Ex-apt@LuCXB, a CD133-targeted and aptamer-functionalized exosome-based nanoparticle photosensitizer. This innovative approach precisely targets and attacks cancer stem cells, thereby enhancing treatment precision while minimizing potential side effects. In vivo experiments conducted on liver and breast cancer mouse models have demonstrated significant antitumor effects, highlighting the practical applications of this targeted strategy and its biocompatibility [7,8]. The mechanism of LuCXB primarily relies on the Type I photodynamic pathway, which generates superoxide radicals upon near-infrared light irradiation. These radicals possess high cytotoxicity within the tumor microenvironment. Additionally, LuCXB exhibits a dual mechanism of action: it inhibits tumor growth through anti-angiogenesis and enhances antitumor immunity via photoinduced immune responses. This synergistic mechanism not only directly attacks tumor cells but also activates the immune system to further eliminate residual cancer cells, thereby reducing the likelihood of tumor recurrence.

Despite the promising potential demonstrated by LuCXB in preliminary studies, further research and optimization are required in several areas. Firstly, it is essential to enhance the photostability of LuCXB to ensure its stability and effectiveness under physiological conditions and during light exposure. Additionally, optimizing the design of the conjugate is crucial for maximizing ROS generation in hypoxic tumor environments [9]. Detailed mechanistic studies are also necessary to elucidate the molecular pathways through which LuCXB induces tumor cell death and its role in immune responses. Understanding how LuCXB adapts and functions in hypoxic environments will further refine its application in solid tumors. On the other hand, biocompatibility and safety are crucial for clinical applications, necessitating comprehensive long-term safety studies

^aDepartment of Chemistry, Korea University, Seoul 02841, Korea^bGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, 518055, China
E-mail: pf.zhang@siat.ac.cn^cEngineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of pharmacy, Chengdu University, Chengdu 610106, China
E-mail: meiling@cdu.edu.cn

† These authors contributed equally to this work.



to evaluate the potential adverse effects of LuCXB and its derivatives *in vivo*. Investigating the impact of repeated treatments on the immune system is also imperative to ensure absence of any unfavourable immune reactions. In terms of clinical translation, developing cost-effective and scalable synthesis methods for LuCXB and related nanoparticle photosensitizers is vital to meet the demands of large-scale production. Navigating the intricate regulatory landscape to ensure compliance with safety and efficacy standards for new therapies poses another significant challenge. Lastly, conducting comparative studies to benchmark the efficacy and safety of LuCXB against existing photodynamic therapy agents

and other cancer treatments is essential in establishing its advantages and clinical potential [10-11]. In summary, the LuCXB represents a significant innovation and potential in the field of immuno-photodynamic therapy. Its efficacy in hypoxic tumor environments and enhanced antitumor effects through dual mechanisms make it a breakthrough in cancer treatment. However, addressing challenges related to conjugate design, mechanistic studies, biocompatibility, safety, clinical translation, and comparative research is crucial for its successful development. By resolving these issues comprehensively, LuCXB and its derivatives have the potential to offer a novel and effective treatment option for cancer patients, instilling new hope into cancer therapy. (Figure 1)




Figure 1 Schematic illustrates the interconversion between dominant type II and type I ROS generation, which is influenced by the surrounding medium as well as the chemical structures. Additionally, it presents a concise synthetic route to produce LuTex-derived conjugates of small molecule photosensitizers containing celecoxib (LuCXB).

Author contributions

We strongly encourage authors to include author contributions and recommend using [CRediT](#) for standardised contribution descriptions. Please refer to our general [author guidelines](#) for more information about authorship.

Conflicts of interest

There are no conflicts to declare.

Data availability

The dataset used in this highlight has been published and is available.

Acknowledgements

The acknowledgements come at the end of an article after the conclusions and before the notes and references.



Notes and references

View Article Online
DOI: 10.1039/D4TB02019G

- 1 Q. Ding, Y. Luo, J. Hu, S. Zhang, W. Zhang, Y. Feng, K. Qian, X. Li, Z. Cheng, M. Gu, *Chem. Eng. J.*, 2024, **495**, 153395.
- 2 J. An, K. Lv, C. V. Chau, J. H. Lim, R. Parida, X. Huang, S. Debnath, Y. Xu, S. Zheng, A. C. Sedgwick, J. Y. Lee, D. Luo, Q. Liu, J. L. Sessler, J. S. Kim, *J. Am. Chem. Soc.*, 2024, **146**, 19434-19448.
- 3 Y. Liu, M. Gu, Q. Ding, Z. Zhang, W. Gong, Y. Yuan, X. Miao, H. Ma, X. Hong, W. Hu, Y. Xiao, *Angew. Chem. Int. Ed.*, 2023, **62**, e202214875.
- 4 Q. Ding, X. Xu, Y. Li, B. Li, Q. Saiping, M. Gu, W. Tao, B. Z. Tang, J. S. Kim, *Chem*, 2024, **10**, 2031-2073.
- 5 S. Li, Q. Ding, L. Zhang, F. Shi, C. Liu, T. Li, Y. Shi, M. Qi, L. Wang, B. Dong, S. Song, J. Sun, J. S. Kim, C. Li, *J. Control. Release*, 2024, **370**, 600-613.
- 6 L. Tu, C. Li, Q. Ding, A. Sharma, M. Li, J. Li, J. S. Kim, Y. Sun, *J. Am. Chem. Soc.*, 2024, **146**, 8991-9003.
- 7 P. Devant, J. C. Kagan, *Nat Immunol*, 2023, **24**, 1064-1075.
- 8 Q. Ding, X. Wang, Y. Luo, X. Leng, X. Li, M. Gu, J. S. Kim, *Coord. Chem. Rev.*, 2024, **508**, 215772.
- 9 Q. Ding, M. He, M. Gu, *Sci. China Chem.*, 2024, **67**, 1-2. <https://doi.org/10.1007/s11426-024-2224-9>.
- 10 Q. Yang, X. Sun, Q. Ding, M. Qi, C. Liu, T. Li, F. Shi, L. Wang, C. Li, J. S. Kim, *Natl. Sci. Rev.*, 2024, **11**, nwae225.
- 11 Q. Ding, L. Mei, Y. Liu, S. Zhou, L. Chen, Y. Liang, M. Li, H. Zhou, C. Yin, J. S. Kim, *Chem. Commun.*, 2023, **59**, 8127-8130.



Data availability statements

This study was carried out using publicly available data from Lutetium Texaphyrin–Celecoxib Conjugate as a Potential Immuno-Photodynamic Therapy Agent Journal of the American Chemical Society at <https://pubs.acs.org/doi/10.1021/jacs.4c05978> with [DOI: 10.1021/jacs.4c05978].

